Gastroesophageal reflux disease (GERD) affects an estimated 20% of the population in the Unites States. Lifestyle modifications and proton pump inhibitor therapy are effective for majority of patients, however, some patients cannot tolerate this treatment or find it ineffective requiring endoscopic or surgical management. Obese patients with GERD who pursue surgical management are at increased risk of developing recurrence of symptoms after laparoscopic anti-reflux surgery. Roux en Y gastric bypass remains the surgical procedure of choice for obese patients with GERD. Endoluminal weight loss interventions seek to offer minimally invasive options for obesity management, however, their efficacy for GERD management in patients with obesity remains to be determined.
CamilleriMDuboisDCoulieB, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US upper gastrointestinal study. Clin Gastroenterol Hepatol. 2005;3(6):543-552.
2.
GawronAJFrenchDDPandolfinoJEHowdenCW.Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics. 2014;32(8):745-758.
3.
El-SeragHBSweetSWinchesterCCDentJ.Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880.
4.
HalesCMFryarCDCarrollMDFreedmanDSOgdenCL.Trends in obesity and severe obesity prevalence in US youth and adults by Sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319(16):1723-1725.
5.
HerregodsTVKBredenoordAJSmoutAJPM. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil. 2015;27(9):1202-1213.
6.
JacobsonBCSomersSCFuchsCSKellyCPCamargoCAJr.Body-mass index and symptoms of gastroesophageal reflux in women. New Engl J Med. 2006;354(22):2340-2348.
7.
HampelHAbrahamNSEl-SeragHB.Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211.
8.
SinghMLeeJGuptaN, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity. 2013;21(2):284-290.
9.
RuigómezAGarcía RodríguezLAWallanderMAJohanssonSEklundS.Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol. 2006;101(12):2685-2692.
10.
BoghossianTARashidFJThompsonW, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969.
11.
SpechlerSJHunterJGJonesKM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. New Engl J Med. 2019;381(16):1513-1523.
12.
JobeBARichterJEHoppoT, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal diagnostic advisory panel. J Am Coll Surg. 2013;217(4):586-597.
13.
MoullaYLyrosOMehdornM, et al. Correction to: preoperative upper-GI endoscopy prior to bariatric surgery: essential or optional?Obes Surg. 2020;30(8):3263-2084.
14.
Di LorenzoNAntoniouSABatterhamRL, et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. Surg Endosc. 2020;34(6):2332-2358.
15.
PeuraDAPilmerBHuntBModyRPerezMC.The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther. 2013;37(8):810-818.
16.
PaceFCoudsyBDeLemosB, et al. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. Eur J Gastroenterol Hepatol. 2011;23(10):845-851.
17.
SheuBSChengHCChangWLChenWYKaoAW.The impact of body mass index on the application of on-demand therapy for Los Angeles grades a and B reflux esophagitis. Am J Gastroenterol. 2007;102(11):2387-2394.
18.
ChenWYChangWLTsaiYCChengHCLuCCSheuBS.Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades a and B. Am J Gastroenterol. 2010;105(5):1046-1052.
19.
MajumderSBirkJ.A review of the current status of endoluminal therapy as a primary approach to obesity management. Surg Endosc. 2013;27(7):2305-2311.
20.
MunirajTDayLWTeigenLM, et al. AGA clinical practice guidelines on intragastric balloons in the management of obesity. Gastroenterology. 2021;160(5):1799-1808.
21.
Al-MomenAEl-MogyI.Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15(1):101-105.
22.
MingroneGvan BaarACDevièreJ, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2021. doi: 10.1136/gutjnl-2020-323608. Epub ahead of print. PMID: 33597157.
23.
de OliveiraGHPde MouraDTHFunariMP, et al. Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis. Obes Surg. 2021;31(3):1304-1312.
24.
FogelRDe FogelJBonillaYDe La FuenteR.Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. Gastrointest Endosc. 2008;68(1):51-58.
25.
BrethauerSAChandBSchauerPRThompsonCC.Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. Surg Obes Relat Dis. 2012;8(3):296-303.
26.
RubanAAshrafianHTeareJP.The EndoBarrier: duodenal-jejunal bypass liner for diabetes and weight loss. Gastroenterol Res Pract. 2018;2018:7823182.
27.
ThompsonCCAbu DayyehBKKushnirV, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis. 2019;15(8):1348-1354.
28.
ThompsonCCAbu DayyehBKKushnerR, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447-457.
29.
AbdelrahmanTLatifAChanDS, et al. Outcomes after laparoscopic anti-reflux surgery related to obesity: a systematic review and meta-analysis. Internet J Surg. 2018;51:76-82.
30.
BashirYChonchubhairHNDugganSN, et al. Systematic review and meta-analysis on the effect of obesity on recurrence after laparoscopic anti-reflux surgery. Surgeon. 2019;17(2):107-118.
31.
TandonARaoRHotourasA, et al. Safety and effectiveness of antireflux surgery in obese patients. Ann R Coll Surg Engl. 2017;99(7):515-523.
32.
StroupDFBerlinJAMortonSC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
33.
AngrisaniLSantonicolaAIovinoPFormisanoGBuchwaldHScopinaroN.Reply to letter to the editor: Bariatric Surgery Worldwide 2013 reveals a rise in mini-gastric bypass. Obes Surg. 2015;25(11):2166-2168.
34.
SalminenPHelmiöMOvaskaJ, et al. Effect of Laparoscopic sleeve gastrectomy vs Laparoscopic Roux-en-Y gastric bypass on weight loss at 5 Years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319(3):241-254.
35.
PeterliRWölnerhanssenBKVetterD, et al. Laparoscopic sleeve gastrectomy versus Roux-y-Gastric bypass for morbid obesity-3-year outcomes of the prospective randomized Swiss multicenter bypass Or sleeve study (SM-BOSS). Ann Surg. 2017;265(3):466-473.
36.
ZhaoHJiaoL.Comparative analysis for the effect of Roux-en-Y gastric bypass vs sleeve gastrectomy in patients with morbid obesity: evidence from 11 randomized clinical trials (meta-analysis). Internet J Surg. 2019;72:216-223.
37.
WölnerhanssenBKPeterliRHurmeS, et al. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). Br J Surg. 2021;108(1):49-57.
38.
YeungKTDPenneyNAshrafianLDarziAAshrafianH. Does sleeve gastrectomy expose the distal esophagus to severe reflux?: a systematic review and meta-analysis. Ann Surg. 2020;271(2):257-265.
39.
AmorIBCasanovaVVanbiervlietG, et al. The Nissen-Sleeve (N-sleeve): results of a cohort study. Obes Surg. 2020;30(9):3267-3272.
40.
BroderickRCSmithCDCheverieJN, et al. Magnetic sphincter augmentation: a viable rescue therapy for symptomatic reflux following bariatric surgery. Surg Endosc. 2020;34(7):3211-3215.
41.
LewJIDaudADiGorgiMFOlivero-RiveraLDavisDGBesslerM.Preoperative esophageal manometry and outcome of laparoscopic adjustable silicone gastric banding. Surg Endosc. 2006;20(8):1242-1247.
42.
de JongJRvan RamshorstBTimmerRGooszenHGSmoutAJ.Effect of laparoscopic gastric banding on esophageal motility. Obes Surg. 2006;16(1):52-58.
